Skip to main content
. 2017 Sep 21;8(52):89761–89774. doi: 10.18632/oncotarget.21125

Figure 3. Targeting Axl inhibits tumor growth partially depending on the immune system.

Figure 3

(A) Schematic regimen for testing the in vivo optimal dose of R428 (top) or R428 treatment in mice depleted of lymphocyte subsets (bottom). (B) C57BL/6 mice (6 per group) bearing 10-day-established ID8 tumors were treated with control vehicle or R428 at the indicated dose for two weeks and their overall survival was evaluated. (C) Nude mice (6 per group) bearing 10-day-established ID8 tumors were treated with R428 at the indicated dose for two weeks and their overall survival was evaluated. (D) C57BL/6 mice (6 per group) bearing 10-day-established ID8 tumors with lymphocyte subset depletion were treated with R428 at the indicated dose for two weeks and their overall survival was evaluated. Data are representative of two (B and D) or three (C) independent experiments, **p < 0.01, ***p < 0.001, log-rank test (B–D).